The Amyotrophic Lateral Sclerosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Amyotrophic Lateral Sclerosis: An Overview
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time.
There is no cure and no proven treatment for ALS. However, available treatments can help control symptoms, prevent unnecessary complications, and make the patient’s life easier. The disease progresses over 3–5 years, making voluntary movements of arms and legs impossible. In time, the patient will need help with personal care, eating, and mobility.
Supportive care is best provided by multidisciplinary teams of healthcare professionals such as physicians, pharmacists, therapists—physical, occupational, and speech—nutritionists, social workers, respiratory therapists, clinical psychologists, and home care and hospice nurses.
Amyotrophic Lateral Sclerosis Market Key Facts
-
The Amyotrophic lateral sclerosis (ALS) prevalent population in the seven major markets was 71,600+ in 2020.
-
The ALS diagnosed prevalent cases in the United States were 18,800+ in 2020.
-
In 2020, the patients with the limb site of onset accounted for 2,500+ cases, followed by 1,200+ cases with the bulbar site of onset, 800+ cases with a cervical site of onset, and 450+ cases with other uncertain regions in Germany.
-
The prevalence of Amyotrophic lateral sclerosis (ALS) is more common in males than in females.
Amyotrophic Lateral Sclerosis Market
Amyotrophic lateral sclerosis (ALS) market size in the seven major markets was USD 401.19 Million in 2020, which is expected to grow during the study period. Amyotrophic lateral sclerosis (ALS) market size is expected to increase during the forecast owing to the rise in the number of diagnosed prevalent cases in the 7MM and the expected launch of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Amyotrophic Lateral Sclerosis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Amyotrophic Lateral Sclerosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Amyotrophic Lateral Sclerosis Epidemiology
The epidemiology section covers insights about the historical and current Amyotrophic Lateral Sclerosis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Amyotrophic Lateral Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to get launched in the market during the study period. The analysis covers Amyotrophic Lateral Sclerosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Amyotrophic Lateral Sclerosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market
Amyotrophic Lateral Sclerosis Therapeutics Analysis
The Amyotrophic lateral sclerosis (ALS) market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecasted period.
Some of the key companies in the Amyotrophic lateral sclerosis (ALS) Market include:
-
Cytokinetics
-
Orphazyme
-
Orion Pharma
-
Brainstorm Cell Therapeutics
-
Biogen
-
AB Science
-
Ionis Pharmaceuticals
-
Clene Nanomedicine
-
Neurosense therapeutics
-
Amylyx
-
MediciNova
-
Biohaven Pharmaceuticals
-
Prilenia Therapeutics
And many others.
Amyotrophic lateral sclerosis (ALS) therapies covered in the report include:
-
ODM-109
-
Arimoclomol
-
Reldesemtiv
-
Verdiperstat
-
NurOwn
-
IC14
-
BIIB067
-
CNM-Au8
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market
Table of Content
1. Key Insights
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Competitive Intelligence Analysis
4. Amyotrophic Lateral Sclerosis Market Overview at a Glance
5. Amyotrophic Lateral Sclerosis Disease Background and Overview
6. Amyotrophic Lateral Sclerosis Patient Journey
7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population
8. Amyotrophic Lateral Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyotrophic Lateral Sclerosis Unmet Needs
10. Key Endpoints of Amyotrophic Lateral Sclerosis Treatment
11. Amyotrophic Lateral Sclerosis Marketed Products
12. Amyotrophic Lateral Sclerosis Emerging Therapies
13. Amyotrophic Lateral Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Amyotrophic Lateral Sclerosis Market Outlook (7 major markets)
16. Amyotrophic Lateral Sclerosis Access and Reimbursement Overview
17. KOL Views on the Amyotrophic Lateral Sclerosis Market.
18. Amyotrophic Lateral Sclerosis Market Drivers
19. Amyotrophic Lateral Sclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market
Other Latest Reports By DelveInsight
DelveInsight’s “Paraganglioma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Paraganglioma market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/